Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iparomlimab + tuvonralimab + albumin-bound paclitaxel
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Iparomlimab + tuvonralimab + albumin-bound paclitaxel is a combination therapy regimen being investigated for the treatment of advanced gastrointestinal malignancies. The regimen consists of **QL1706**, a bifunctional antibody product developed by **Qilu Pharmaceutical** that combines the anti-PD-1 monoclonal antibody **iparomlimab** and the anti-CTLA-4 monoclonal antibody **tuvonralimab**, administered alongside **albumin-bound paclitaxel** (nab-paclitaxel). QL1706 is designed to simultaneously block two key immune checkpoints, thereby enhancing the activation and proliferation of T-cells against tumor cells. Albumin-bound paclitaxel is a nanoparticle formulation of the taxane chemotherapy agent paclitaxel, which stabilizes microtubules to inhibit cell division. This combination is currently being evaluated in Phase 2 clinical trials (such as those led by investigator **Qingxia Li**) as a second-line treatment for patients with advanced **gastric adenocarcinoma** or **gastroesophageal junction (GEJ) adenocarcinoma** who have failed prior therapies.
- Brand names
- Qibei'an + nab-paclitaxel
- Other names
- QL1706 + albumin-bound paclitaxelIparomlimab/Tuvonralimab + nab-paclitaxel
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on iparomlimab + tuvonralimab + albumin-bound paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iparomlimab + tuvonralimab + albumin-bound paclitaxel.